The CDMO Vetter has received a Red Dot Award in the Design Concept category for its V-OVS syringe closure system.
Announced on Thursday, the award recognises the next-generation design of the closure technology, which builds on more than 20 years of market success.
The system addresses the evolving needs of pharma and biotech companies, particularly as biologics and other complex injectable medicines place greater demands on drug delivery systems.
What is the Red Dot Award?
The Red Dot Design Award is an international design competition that recognises innovation and design quality across product design, brands and communication design and design concepts.
The Design Concept category evaluates concepts, prototypes and products at different stages of development.
Its judging criteria include innovation, functionality, aesthetic quality, feasibility, user experience and potential impact.
An award therefore recognises an entry's design merits; it does not, by itself, indicate regulatory approval or clinical validation.
For pharma packaging, the recognition highlights the importance of considering usability and handling alongside technical functionality when developing components for injectable drug delivery.
A next-gen take on syringe closure
V-OVS next incorporates several design features intended to improve safety, usability and compatibility across different syringe formats.
Its locking mechanism provides a secure connection between the syringe and closure component, helping reduce unintended rotation.
The system also features a tamper-evident seal that irreversibly breaks when first opened, providing a visible indication that the closure has been accessed.
This is intended to support product integrity and give users greater confidence when handling injectable medicines.
Ergonomic gripping elements and integrated visual opening indicators are designed to make the closure easier to handle intuitively.
The system also combines these functional considerations with a premium appearance, potentially helping pharmaceutical companies differentiate their injectable products through packaging design.
Dr Claus Feussner, Senior Vice President Development Service at Vetter, said the development process combined technical innovation with user insights, with a focus on functionality, patient safety and intuitive handling.
Vetter builds on injectable manufacturing capability
The recognition comes as Vetter continues to invest in its global injectable drug manufacturing capabilities.
In September 2026, the company outlined plans to add ten production lines by 2032, including seven filling lines at existing sites and three at its planned commercial manufacturing facility in Saarlouis, Germany.
Its first new line for pre-sterilised syringes is already operational, with a second planned by the end of this year.
Vetter’s expansion plans form part of a wider strategy to support demand for injectable therapies.
